Renaissance Technologies LLC Acquires Shares of 130,500 Patheon NV (PTHN)
Renaissance Technologies LLC acquired a new stake in Patheon NV (NASDAQ:PTHN) during the first quarter, according to its most recent filing with the SEC. The firm acquired 130,500 shares of the company’s stock, valued at approximately $3,437,000.
Other large investors have also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in Patheon NV by 40.5% in the fourth quarter. State Street Corp now owns 389,959 shares of the company’s stock valued at $11,194,000 after buying an additional 112,322 shares during the last quarter. Guggenheim Capital LLC purchased a new stake in Patheon NV during the fourth quarter valued at about $324,000. Lazard Asset Management LLC boosted its stake in Patheon NV by 12.6% in the first quarter. Lazard Asset Management LLC now owns 111,575 shares of the company’s stock valued at $2,938,000 after buying an additional 12,475 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Patheon NV by 47.6% in the first quarter. Ameriprise Financial Inc. now owns 1,803,720 shares of the company’s stock valued at $47,511,000 after buying an additional 581,914 shares during the last quarter. Finally, Blair William & Co. IL purchased a new stake in Patheon NV during the first quarter valued at about $275,000.
Shares of Patheon NV (PTHN) traded down 0.014% on Friday, reaching $34.965. 35,822 shares of the company were exchanged. The company has a 50-day moving average price of $34.90 and a 200 day moving average price of $31.16. Patheon NV has a 1-year low of $23.72 and a 1-year high of $35.02. The stock has a market capitalization of $5.07 billion and a PE ratio of 44.827.
Patheon NV (NASDAQ:PTHN) last issued its quarterly earnings data on Thursday, June 8th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.01. The firm had revenue of $483.40 million during the quarter, compared to analyst estimates of $466.08 million. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. On average, analysts forecast that Patheon NV will post $1.14 EPS for the current fiscal year.
PTHN has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Patheon NV from a “buy” rating to a “hold” rating in a research report on Thursday, June 15th. Raymond James Financial, Inc. restated a “market perform” rating and set a $35.00 price objective on shares of Patheon NV in a research report on Thursday, June 8th. J P Morgan Chase & Co cut shares of Patheon NV from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. Jefferies Group LLC cut shares of Patheon NV from a “buy” rating to a “hold” rating and lifted their price target for the company from $32.00 to $35.00 in a research report on Tuesday, May 16th. Finally, Leerink Swann cut shares of Patheon NV from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $31.00 to $35.00 in a research report on Friday, June 9th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $32.88.
Patheon NV Company Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Want to see what other hedge funds are holding PTHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Patheon NV (NASDAQ:PTHN).
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with Analyst Ratings Network's FREE daily email newsletter.